12:00 AM
 | 
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Zemplar paricalcitol: Phase IV data

The open-label, international Phase IV IMPACT-SHPT trial in 272 patients showed that a significantly greater proportion of patients receiving IV Zemplar achieved mean intact PTH levels of 150-300 pg/mL during weeks 21-28, the primary endpoint, vs. IV cinacalcet plus low-dose vitamin D...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >